1. Home
  2. HRTX vs LUNG Comparison

HRTX vs LUNG Comparison

Compare HRTX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heron Therapeutics Inc.

HRTX

Heron Therapeutics Inc.

HOLD

Current Price

$0.33

Market Cap

90.1M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.27

Market Cap

97.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRTX
LUNG
Founded
1983
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.1M
97.1M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
HRTX
LUNG
Price
$0.33
$2.27
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$4.50
$5.38
AVG Volume (30 Days)
3.0M
896.1K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$154,904,000.00
$90,497,000.00
Revenue This Year
$15.28
$2.48
Revenue Next Year
$20.29
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
7.36
8.01
52 Week Low
$0.30
$1.13
52 Week High
$1.58
$2.89

Technical Indicators

Market Signals
Indicator
HRTX
LUNG
Relative Strength Index (RSI) 33.92 64.29
Support Level N/A $2.16
Resistance Level $0.46 $2.44
Average True Range (ATR) 0.04 0.19
MACD -0.01 -0.00
Stochastic Oscillator 13.17 67.48

Price Performance

Historical Comparison
HRTX
LUNG

About HRTX Heron Therapeutics Inc.

Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: